Evidence map›Paper›PMID 25794130›Full record

Trial reportBlood cancer journal2015

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.

V Roy, A K Stewart, P L Bergsagel, A Dispenzieri, K Laumann, J Allred, M Q Lacy, R Fonseca, C B Reeder, S Kumar and 5 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

V RoyHematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
A K StewartHematology, Mayo Clinic, Scottsdale, AZ, USA.
P L BergsagelHematology, Mayo Clinic, Scottsdale, AZ, USA.
A DispenzieriHematology, Mayo Clinic, Rochester, MN, USA.
K LaumannBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
J AllredBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
M Q LacyHematology, Mayo Clinic, Rochester, MN, USA.
R FonsecaHematology, Mayo Clinic, Scottsdale, AZ, USA.
C B ReederHematology, Mayo Clinic, Scottsdale, AZ, USA.
S KumarHematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000000153929284
C E RiveraHematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
M A GertzHematology, Mayo Clinic, Rochester, MN, USA.
F K BuadiHematology, Mayo Clinic, Rochester, MN, USA.
S R HaymanHematology, Mayo Clinic, Rochester, MN, USA.
S V RajkumarHematology, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLenalidomideMaleMelphalanMiddle AgedMultiple MyelomaPrednisoneStem Cell TransplantationThalidomideLenalidomideMelphalanPrednisoneThalidomide

Identifiers

PMID25794130
PMCPMC4382664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.